Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257242 · ClinicalTrials.gov registry record · Phase 1
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
A Phase 1 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02257242 is a Phase 1 study that has completed, run by Brown University. The registered enrollment target is 11 participants.
The verdict
NCT02257242, a Phase 1 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.
Interventions
- DRUG Rituximab
- DRUG Bendamustine
- DRUG Vincristine sulfate liposome injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257242
The ClinicalTrials.gov registry entry for NCT02257242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT02257242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02257242 about?
NCT02257242 is a clinical study titled "Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma". This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.
What is the current status of trial NCT02257242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-05-10. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT02257242?
The interventions under investigation include: Rituximab (DRUG), Bendamustine (DRUG), Vincristine sulfate liposome injection (DRUG).
Who is sponsoring clinical trial NCT02257242?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.